These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer. Iida K; Naiki T; Kawai N; Etani T; Ando R; Ikegami Y; Okamura T; Kubota H; Okada A; Kohri K; Yasui T BMC Urol; 2016 Feb; 16():8. PubMed ID: 26920373 [TBL] [Abstract][Full Text] [Related]
26. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315 [TBL] [Abstract][Full Text] [Related]
27. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design. Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408 [TBL] [Abstract][Full Text] [Related]
28. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482 [TBL] [Abstract][Full Text] [Related]
36. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Lundholm C; Norlén BJ; Ekman P; Jahnson S; Lagerkvist M; Lindeborg T; Olsson JL; Tveter K; Wijkstrom H; Westberg R; Malmström PU J Urol; 1996 Aug; 156(2 Pt 1):372-6. PubMed ID: 8683682 [TBL] [Abstract][Full Text] [Related]
37. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. Krege S; Giani G; Meyer R; Otto T; Rübben H J Urol; 1996 Sep; 156(3):962-6. PubMed ID: 8709374 [TBL] [Abstract][Full Text] [Related]
38. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer. Ajili F; Darouiche A; Chebil M; Boubaker S Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613 [TBL] [Abstract][Full Text] [Related]
39. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. de Reijke TM; de Boer EC; Kurth KH; Schamhart DH J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640 [TBL] [Abstract][Full Text] [Related]
40. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. Witjes JA; Dalbagni G; Karnes RJ; Shariat S; Joniau S; Palou J; Serretta V; Larré S; di Stasi S; Colombo R; Babjuk M; Malmström PU; Malats N; Irani J; Baniel J; Cai T; Cha E; Ardelt P; Varkarakis J; Bartoletti R; Spahn M; Pisano F; Gontero P; Sylvester R Urol Oncol; 2016 Nov; 34(11):484.e19-484.e25. PubMed ID: 27639776 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]